ANIP FY 2019 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

FY 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$207M+2.5% YoY

Gross Profit

$143M69.4% margin

Operating Income

$16M7.9% margin

Net Income

$6M3.0% margin

EPS (Diluted)

$0.50

Cash Flow

Operating Cash Flow

$46M

Free Cash Flow

$18M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$457M

Total Liabilities

$244M

Stockholders' Equity

$213M

Cash & Equivalents

$62M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$207M	$202M	+2.5%
Gross Profit	$143M	$129M	+11.5%
Operating Income	$16M	$35M	-53.8%
Net Income	$6M	$15M	-60.7%